BRPI0905656B8 - anticorpo humanizado a9-integrina anti-humana, fármaco terapêutico para artrite rematóide e uso do anticorpo humanizado a9-integrina anti-humana. - Google Patents
anticorpo humanizado a9-integrina anti-humana, fármaco terapêutico para artrite rematóide e uso do anticorpo humanizado a9-integrina anti-humana.Info
- Publication number
- BRPI0905656B8 BRPI0905656B8 BRPI0905656A BRPI0905656A BRPI0905656B8 BR PI0905656 B8 BRPI0905656 B8 BR PI0905656B8 BR PI0905656 A BRPI0905656 A BR PI0905656A BR PI0905656 A BRPI0905656 A BR PI0905656A BR PI0905656 B8 BRPI0905656 B8 BR PI0905656B8
- Authority
- BR
- Brazil
- Prior art keywords
- integrin
- alpha
- humanized
- human
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
anticorpo humanizado (alfa)9-integrina anti-humana, polinucleotideo, vetor de expressão, célula hospedeira, método para produzir um anticorpo humanizado (alfa)9-integrina anti-humana, fármaco terapêutico para artrite reumatóide, método para prevenir ou tratar artrite reumatóide e uso do anticorpo humanizado (alfa)9-integrina anti-humana. a presente invenção provê um anticorpo (alfa)9-integrina anti- humano humanizado tendo urna atividade melhorada e/ou propriedade quanto comparado para a um anticorpo (alfa)9-integrina anti-humano humanizado de um camundongo doador, denominado anticorpo (alfa)9-integrina anti-humano humanizado contendo uma região variável de cadeia pesada consistindo da seqüência de aminoácido mostrada pela seq id no:11 e uma região variável de cadeia leve consistindo da seqüência de aminoácidos mostrado pela seq id no:17, um anticorpo (alfa)9-integrina anti-humana humanizada contendo uma região variável de cadeia pesa consistindo da seqüência de aminoácidos mostrada pela seq id no:13 e uma região variável de cadeia leve consistindo da seqüência de aminoácidos mostrada pela seq id no:17, um anticorpo (alfa)9-integrina anti-humano humanizado contendo uma região variável de cadeia pesada consistindo da seqüência de aminoácidos mostrada pela seq id no:15 e uma região variável de cadeia leve consistindo da seqüência de aminoácidos mostrada pela seq id no:9, e um meio para a profilaxia ou o tratamento de várias doenças envolvendo a (alfa)9-integrina humana na patogênese, que utiliza o anticorpo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008-004975 | 2008-01-11 | ||
| JP2008004975 | 2008-01-11 | ||
| JP2008282496 | 2008-10-31 | ||
| JP2008-282496 | 2008-10-31 | ||
| PCT/JP2009/050187 WO2009088064A1 (ja) | 2008-01-11 | 2009-01-09 | 改良型ヒト化抗ヒトα９インテグリン抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0905656A2 BRPI0905656A2 (pt) | 2015-07-07 |
| BRPI0905656A8 BRPI0905656A8 (pt) | 2017-05-09 |
| BRPI0905656B1 BRPI0905656B1 (pt) | 2020-03-31 |
| BRPI0905656B8 true BRPI0905656B8 (pt) | 2021-05-25 |
Family
ID=40853174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0905656A BRPI0905656B8 (pt) | 2008-01-11 | 2009-01-09 | anticorpo humanizado a9-integrina anti-humana, fármaco terapêutico para artrite rematóide e uso do anticorpo humanizado a9-integrina anti-humana. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8603476B2 (pt) |
| EP (2) | EP2243829B1 (pt) |
| JP (2) | JPWO2009088065A1 (pt) |
| KR (1) | KR101634636B1 (pt) |
| CN (1) | CN101918549B (pt) |
| AU (1) | AU2009203369B2 (pt) |
| BR (1) | BRPI0905656B8 (pt) |
| CA (1) | CA2711882C (pt) |
| CY (1) | CY1115897T1 (pt) |
| DK (1) | DK2243829T3 (pt) |
| ES (1) | ES2519047T3 (pt) |
| HR (1) | HRP20141110T1 (pt) |
| IL (1) | IL206898A (pt) |
| MX (1) | MX2010007515A (pt) |
| PL (1) | PL2243829T3 (pt) |
| PT (1) | PT2243829E (pt) |
| RU (1) | RU2503720C2 (pt) |
| SI (1) | SI2243829T1 (pt) |
| TW (1) | TWI432453B (pt) |
| WO (2) | WO2009088064A1 (pt) |
| ZA (1) | ZA201004770B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2575047B2 (ja) | 1988-05-31 | 1997-01-22 | 横河電機株式会社 | ディジタル画像の復元装置 |
| EP2406285B1 (en) * | 2009-03-10 | 2016-03-09 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized k33n monoclonal antibody |
| WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| AU2012252152B2 (en) * | 2011-05-06 | 2016-07-07 | Zoetis Services Llc | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| HK1201281A1 (en) * | 2011-10-13 | 2015-08-28 | Nexvet Australia Pty Ltd | Canine/feline cd20 binding epitope and compositions for binding thereto |
| JP2021008406A (ja) * | 2017-09-29 | 2021-01-28 | アステラス製薬株式会社 | 改良型ヒト化抗ヒトα９インテグリン抗体含有医薬組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE69433422T2 (de) | 1993-03-11 | 2004-09-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Monoklonaler anti-hiv antikörper |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
| PL366469A1 (en) | 2001-04-05 | 2005-02-07 | Immuno-Biological Laboratories Co, Ltd. | Anti-osteopontin antibody and use thereof |
| RU2305111C2 (ru) * | 2001-09-25 | 2007-08-27 | Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют | Рекомбинантное антитело против остеопонтина и его применение |
| AU2003256307A1 (en) * | 2002-06-25 | 2004-01-06 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
| ES2377979T3 (es) | 2004-09-03 | 2012-04-03 | Genentech, Inc. | Antagonistas anti-beta7 humanizados y utilizaciones para los mismos |
| KR101316990B1 (ko) * | 2005-01-13 | 2013-10-11 | 가부시키가이샤 진 테크노 사이언스 | 항-α9 인테그린 항체와 그 용도 |
| BRPI0711229A2 (pt) | 2006-05-31 | 2013-01-08 | Astellas Pharma Inc | anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana |
| JP4841326B2 (ja) | 2006-06-20 | 2011-12-21 | 三菱電機株式会社 | ホームネットワークシステム |
| JP5066087B2 (ja) * | 2006-07-12 | 2012-11-07 | 株式会社ジーンテクノサイエンス | 抗ヒトα９インテグリン抗体とその用途 |
| JP2008282496A (ja) | 2007-05-11 | 2008-11-20 | Konica Minolta Opto Inc | 光ピックアップ装置 |
| JP2007302676A (ja) * | 2007-05-29 | 2007-11-22 | Genentech Inc | ヒト化抗β７アンタゴニストおよびその使用 |
-
2009
- 2009-01-09 MX MX2010007515A patent/MX2010007515A/es active IP Right Grant
- 2009-01-09 US US12/812,341 patent/US8603476B2/en not_active Expired - Fee Related
- 2009-01-09 RU RU2010133550/10A patent/RU2503720C2/ru active
- 2009-01-09 CN CN2009801019731A patent/CN101918549B/zh not_active Expired - Fee Related
- 2009-01-09 KR KR1020107017150A patent/KR101634636B1/ko not_active Expired - Fee Related
- 2009-01-09 JP JP2009548962A patent/JPWO2009088065A1/ja not_active Abandoned
- 2009-01-09 EP EP09700904.7A patent/EP2243829B1/en active Active
- 2009-01-09 PT PT97009047T patent/PT2243829E/pt unknown
- 2009-01-09 ES ES09700904.7T patent/ES2519047T3/es active Active
- 2009-01-09 DK DK09700904.7T patent/DK2243829T3/da active
- 2009-01-09 JP JP2009548961A patent/JP5440179B2/ja not_active Expired - Fee Related
- 2009-01-09 AU AU2009203369A patent/AU2009203369B2/en not_active Ceased
- 2009-01-09 EP EP09700866A patent/EP2239323A4/en not_active Withdrawn
- 2009-01-09 PL PL09700904T patent/PL2243829T3/pl unknown
- 2009-01-09 HR HRP20141110AT patent/HRP20141110T1/hr unknown
- 2009-01-09 CA CA2711882A patent/CA2711882C/en active Active
- 2009-01-09 WO PCT/JP2009/050187 patent/WO2009088064A1/ja not_active Ceased
- 2009-01-09 SI SI200931034T patent/SI2243829T1/sl unknown
- 2009-01-09 TW TW098100558A patent/TWI432453B/zh not_active IP Right Cessation
- 2009-01-09 WO PCT/JP2009/050188 patent/WO2009088065A1/ja not_active Ceased
- 2009-01-09 BR BRPI0905656A patent/BRPI0905656B8/pt not_active IP Right Cessation
- 2009-07-09 US US12/812,368 patent/US20110014193A1/en not_active Abandoned
-
2010
- 2010-07-06 ZA ZA2010/04770A patent/ZA201004770B/en unknown
- 2010-07-08 IL IL206898A patent/IL206898A/en active IP Right Grant
-
2014
- 2014-11-12 CY CY20141100944T patent/CY1115897T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012021327B8 (pt) | anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo. | |
| BR112012012912A2 (pt) | anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra. | |
| UA105009C2 (uk) | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20121560A1 (es) | Anticuerpos humanizados contra el receptor alfa de la interleucina 22 humana | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
| ECSP12011584A (es) | Anticuerpos anti-vegf y sus usos | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| BR112012021329A2 (pt) | anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo. | |
| PE20121691A1 (es) | Formulacion de anticuerpos y regimenes terapeuticos | |
| AR051888A1 (es) | Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos | |
| CL2007001488A1 (es) | Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina. | |
| AR088289A1 (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion | |
| EA201992570A1 (ru) | Составы на основе человеческих антител к rankl, а также способы их применения | |
| CL2009000618A1 (es) | Uso de anticuerpo monoclonal humanizado th1, que reconoce el dominio 1 del cd6 humano, para preparar un medicamento útil en el tratamiento de la diabetes tipo-1. | |
| RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
| AR082149A1 (es) | Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso | |
| AR073978A1 (es) | Anticuerpos humanos de alta afinidad para el receptor il-4-humano | |
| PE20140625A1 (es) | ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS | |
| HRP20190752T1 (hr) | Novo protutijelo protiv ljudskog receptora tslp | |
| EA201490433A1 (ru) | Новое антитело против ngf человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: ASTELLAS PHARMA INC. (JP) , THE CHEMO-SERO-THERAPE |
|
| B25G | Requested change of headquarter approved |
Owner name: ASTELLAS PHARMA INC. (JP) , THE CHEMO-SERO-THERAPE |
|
| B25A | Requested transfer of rights approved |
Owner name: ASTELLAS PHARMA INC. (JP) |
|
| B25G | Requested change of headquarter approved |
Owner name: ASTELLAS PHARMA INC. (JP) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2756 DE 31-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |